Novo Nordisk Outruns $75 Million Ransomware Demand With Oral Wegovy Scripts and a China Gambit
19.06.2026 - 17:47:30 | boerse-global.de
Novo Nordisk finds itself waging a war on two fronts this week. While two separate cybercriminal groups — FulcrumSec and TheUSERS007 — are demanding a combined $75 million in ransom after stealing pseudonymized patient data from clinical trials, the Danish pharma giant is simultaneously pressing ahead with the most ambitious commercial expansion in its history. The contrast could hardly be starker: one hand fending off hackers, the other placing a blockbuster bet on oral Wegovy.
The ransomware attack, confirmed on June 11, exposed patient IDs, gender, birth dates, and health data from clinical studies. Novo Nordisk refused both the $25 million demand from FulcrumSec and the $50 million demand from TheUSERS007. The incident underscores a growing sector-wide vulnerability: the targeting of proprietary research data and algorithmic know-how in drug development. But the operational hiccup has done little to dampen investor sentiment so far. The stock closed at €39.25 on Friday, a gain of more than 4%, after Berenberg analyst Kerry Holford lifted the price target from 300 to 325 Danish kroner and reiterated a buy rating following a meeting with Novo Nordisk’s US chief.
The real catalyst is oral Wegovy. Since the 25-milligram tablet launched in Europe, it has racked up more than 3 million prescriptions in just over five months, making it the fastest GLP-1 rollout in the region. The UK regulator’s approval earlier this month marked the first oral obesity therapy on the continent, and CEO Mike Doustdar used his maiden visit to China to announce plans to file for approval there within months. That puts Novo Nordisk on a collision course with Eli Lilly, which submitted its oral candidate Orforglipron in China at the end of 2025. The stakes are high: China is the world’s second-largest pharma market, but Novo Nordisk faces a ticking clock — Semaglutide’s patent protection in the country expired in March, and generic competition is expected to arrive as early as the second quarter of 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Beyond Wegovy, the pipeline story revolves around CagriSema, the combination therapy that showed striking weight-reduction results in pivotal trials. Novo Nordisk submitted the US application in December 2025, and an FDA decision is expected in the fourth quarter of 2026. If approved, CagriSema would provide a much-needed second pillar in a product portfolio that has been under pressure from aggressive US pricing. The company slashed list prices for its obesity drugs earlier this year, compressing first-quarter revenue, but the strategy relies on volume to compensate. The 3 million oral Wegovy prescriptions in five months suggest that calculation is working.
Even with the recent bounce, the stock remains 40% below its all-time high of €65.20, weighed down by pricing concerns and the looming threat of generics. Berenberg now expects Novo Nordisk to hit the upper end of its full-year guidance, and the next major test arrives on August 5, when the company reports first-half results. Between the ransomware crisis, the China race, and a pivotal FDA verdict on CagriSema, this summer is shaping up as a defining period for a company trying to turn the page on a brutal selloff.
Ad
Novo Nordisk Stock: New Analysis - 19 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
